[Improvement of insulin sensitivity associated with the prolonged use of Acipimox in ++a morbid obese patient].
Insulin sensitivity was estimated in a morbidity obese, insulin-resistant, glucose-intolerant patient before and after 4 weeks of treatment with Acipimox (250 mg t.i.d), an orally-administered, long-acting antilypolitic drug. The ensuing fall in circulating levels of fasting free fatty acids was associated with a clear amelioration of insulin resistance, as assessed by a minimal model analysis of a frequently sampled intravenous glucose tolerance test as well as by an oral glucose tolerance test. Similarly, this treatment brought about a reappearance of GH response to oral stimulation with clonidine. The evidence showing Acipimox-induced amelioration of insulin resistance in this patient without diet, exercise or weight loss should encourage exploring the potential utility of this drug in this type of patients.
Zura
M L
ML
Sección Endocrinología, Facultad de Medicina (Campus Norte), Universidad de Chile, Hospital José, Joaquín Aguirre.
Contreras
P
P
Aguirre
C
C
Araya
V
V
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D009767:Obesity, Morbid / Q000097:blood / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D013997:Time Factors
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D007328:Insulin; D011719:Pyrazines; C027696:acipimox
Mejoría de la insulinosensibilidad asociada al uso prolongado de Acipimox en un obeso mórbido.